NEW YORK (GenomeWeb) – PGXL Technologies said on Monday it has been awarded $149,910 to fund the development of a platform for isolating and analyzing circulating tumor cells in breast cancer.

The funding is being awarded through the Kentucky Small Business Innovation Research and Small Business Technology Transfer Matching Funds program, and will be used to match a National Institutes of Health/National Cancer Institute grant contract awarded to PGXL in the fall, the firm said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.